Can Longitudinal Biomarkers Guide Treatment Decisions? Time Will Tell.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 39932719.
- Also identified by DOI 10.1158/1078-0432.CCR-24-4297.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Defining patterns of acquired resistance has important prognostic and therapeutic implications in patients with lung cancer. Longitudinal biomarker analysis has enhanced our understanding of tumor biology and treatment response. However, the role of temporally informed biomarkers in guiding clinical decisions, such as local therapy intervention, remains unproven. See related article by Mazzaschi et al., p. 1533.
Medical subject headings
- Biomarkers, Tumor
- Lung Neoplasms
- Clinical Decision-Making